Vericel (VCEL) to Release Earnings on Thursday

Vericel (NASDAQ:VCEL) is projected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $76.47 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Vericel Stock Up 0.4 %

VCEL opened at $52.52 on Wednesday. The business has a 50 day moving average price of $57.48 and a two-hundred day moving average price of $51.75. The company has a market cap of $2.59 billion, a PE ratio of 875.48 and a beta of 1.72. Vericel has a 52 week low of $39.12 and a 52 week high of $63.00.

Insider Buying and Selling

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the sale, the director now owns 26,595 shares in the company, valued at $1,662,187.50. This represents a 8.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jonathan Mark Hopper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $58.72, for a total value of $587,200.00. Following the completion of the sale, the insider now owns 58,371 shares in the company, valued at approximately $3,427,545.12. This represents a 14.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,100 shares of company stock worth $1,206,072 in the last quarter. Company insiders own 5.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on VCEL shares. Stephens reiterated an “overweight” rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. BTIG Research boosted their target price on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Finally, Canaccord Genuity Group boosted their target price on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Vericel currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.14.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.